Role of cholesterol metabolism in the anticancer pharmacology of selective estrogen receptor modulators by Gómez-Coronado, D, Lasunción, MA, Martínez-Botas, J, Fernandez-Suarez, ME

“…Selective estrogen receptor modulators (SERMs) are a class of compounds that bind to estrogen receptors (ERs) and possess estrogen agonist or antagonist actions in different tissues. …”

Selective estrogen receptor modulators (SERMs) affect cholesterol homeostasis through the master regulators SREBP and LXR by Fernandez-Suarez, ME, Daimiel, L, Villa-Turégano, G, Pavón, MV, Busto, R, Escolà-Gil, JC, Platt, FM, Lasunción, MA, Martínez-Botas, J, Gómez-Coronado, D

“…Selective estrogen receptor modulators (SERMs) are nonsteroidal drugs that display an estrogen‐agonist or estrogen‐antagonist effect depending on the tissue targeted. …”

Selective estrogen receptor modulator inhibits osteocyte apoptosis during estrogen loss. Implications for bone quality maintenance by Huber, C, Collishaw, S, Mosley, JR, Taylor, C, Reeve, J, Noble, B

Clinically used selective estrogen receptor modulators affect different steps of macrophage-specific reverse cholesterol transport. by Fernández-Suárez, ME, Escolà-Gil, JC, Pastor, O, Dávalos, A, Blanco-Vaca, F, Lasunción, MA, Martínez-Botas, J, Gómez-Coronado, D

“…Selective estrogen receptor modulators (SERMs) are widely prescribed drugs that alter cellular and whole-body cholesterol homeostasis. …”

Selective estrogen receptor modulator inhibits osteocyte apoptosis during abrupt estrogen withdrawal: implications for bone quality maintenance. by Huber, C, Collishaw, S, Mosley, JR, Reeve, J, Noble, B

“…Ideally, selective estrogen receptor modulators (SERMs) confer all of the positive bone-associated effects of estrogens without any adverse effects. …”

A selective estrogen receptor modulator (SERM) inhibits osteocyte apoptosis during estrogen loss. Implications for bone quality maintenance. by Collishaw, S, Mosley, J, Taylor, C, Reeve, J, Noble, B

A selective estrogen receptor modulator (SERM) inhibits osteocyte apoptosis during estrogen loss. Implications for bone quality maintenance by Collishaw, S, Mosley, J, Taylor, C, Reeve, J, Noble, B

Synthesis, biological evaluation, and stability studies of raloxifene mono- and bis-sulfamates as dual-targeting agents by Zaraei, S-O, Dohle, W, Anbar, HS, El-Gamal, R, Leblond, B, Foster, PA, Al-Tel, TH, Potter, BVL, El-Gamal, MI

“…All three possible sulfamate derivatives of the selective estrogen receptor modulator Raloxifene (bis-sulfamate 7 and two mono-sulfamates 8–9) were synthesized and evaluated as inhibitors of the clinical drug target steroid sulfatase (STS), both in cell-free and in cell-based assays, and also as estrogen receptor (ER) modulators. …”

A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis by Ngan, N, Mai, N, Tung, N, Lan, N, Tai, L, Phu, N, Chau, N, Binh, T, Hung, L, Beardsley, J, White, N, Lalloo, D, Krysan, D, Hope, W, Geskus, R, Wolbers, M, Nhat, L, Thwaites, G, Kestelyn, E, Day, J

“…Tamoxifen, a selective estrogen receptor modulator used to treat breast cancer, has anti-cryptococcal activity, appearing synergistic when combined in vitro with amphotericin, and fungicidal when combined with fluconazole. …”

Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. by Rizzoli, R, Reginster, J, Boonen, S, Bréart, G, Diez-Perez, A, Felsenberg, D, Kaufman, J, Kanis, J, Cooper, C

“…Cutaneous effects and osteonecrosis of the jaw are of concern for denosumab (both very rare), though there are no pharmacovigilance data for this agent yet. The selective estrogen receptor modulators are associated with hot flushes, leg cramps, and, very rarely, venous thromboembolism and stroke. …”

Assessment of cardiovascular safety of anti-osteoporosis drugs by Fuggle, NR, Cooper, C, Harvey, NC, Al-Daghri, N, Brandi, M-L, Bruyere, O, Cano, A, Dennison, EM, Diez-Perez, A, Kaufman, J-M, Palacios, S, Prieto Alhambra, D, Rozenberg, S, Thomas, T, Tremollieres, F, Rizzoli, R, Kanis, JA, Reginster, JY

“…Despite findings in the early 21st century that menopausal hormone therapy was associated with coronary artery disease and venous thromboembolism (VTE), this therapy is now thought to be potentially safe (from a cardiac perspective) if started within the first 10 years of the menopause. Selective estrogen receptor modulators (SERMs) are associated with increased risk of VTE and may be related to fatal strokes (a subset of total strokes). …”

Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the... by Cooper, C, Reginster, J, Cortet, B, Diaz-Curiel, M, Lorenc, R, Kanis, J, Rizzoli, R

“…METHODS: We reviewed the efficacy and safety of calcium and vitamin D, the selective estrogen receptor modulators (SERMs), the bisphosphonates, denosumab, and strontium ranelate in studies of 3 years or longer. …”

The impact of different strategies to handle missing data on both precision and bias in a drug safety study: a multidatabase multinational population-based cohort study by Martin-Merino, E, Calderón-Larrañaga, A, Hawley, S, Poblador-Plou, B, Llorente, A, Petersen, I, Prieto-Alhambra, D

“…<strong>Methods:</strong> New users of AOM (alendronic acid, other bisphosphonates, strontium ranelate, selective estrogen receptor modulators, teriparatide, or denosumab) aged ≥50 years during 1998–2014 were identified in two Spanish (the Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria [BIFAP] and EpiChron cohort) and one UK (Clinical Practice Research Datalink [CPRD]) EMR. …”

Secular trends of use of anti-osteoporosis treatments in Spain: a population-based cohort study including over 1.5 million people and more than 12 years of follow-up by Martín-Merino, E, Huerta-Álvarez, C, Prieto-Alhambra, D, Álvarez-Gutiérrez, A, Montero-Corominas, C

“…Participants entered the study when aged ≥50 years in 2001-2013 and after 1 year of data available, and were followed to an AOM prescription (including alendronate, other bisphosphonates, SERM (selective estrogen receptor modulators), strontium ranelate, teriparatide or denosumab), death, lost or the end of December 2013. …”

Comparative anti-fracture effectiveness of different oral anti-osteoporosis therapies based on “real-world” data: a meta-analysis of propensity-matched cohort findings from the UK... by Khalid, S, Calderon-Larrañaga, S, Hawley, S, Ali, M, Judge, A, Arden, N, Van Staa, T, Cooper, C, Javaid, M, Prieto-Alhambra, D

“…Users of alendronate (reference group) were compared to those of (1) OBP, (2) strontium ranelate (SR), and (3) selective estrogen receptor modulators (SERMs), after matching on baseline characteristics using propensity scores. …”